This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| nonsteroidal anti-inflammatory drugs | |
|---|---|
| Name | Nonsteroidal anti-inflammatory drugs |
| Tradename | NSAIDs |
| Drugs | Aspirin, Ibuprofen, Naproxen, Celecoxib, Diclofenac |
| Class | Analgesics; anti-inflammatory agents |
| ATC prefix | M01 |
nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of analgesic and anti-inflammatory agents widely used to treat pain, fever, and inflammation. They are commonly prescribed for conditions ranging from acute musculoskeletal injuries to chronic rheumatologic disorders and are available in both prescription and over-the-counter forms across many countries. Major international organizations, academic medical centers, regulatory agencies, and pharmaceutical companies have influenced their development, standardization, and clinical guidelines.
NSAIDs are indicated for symptomatic relief in acute conditions such as low back pain, tension headache, dental pain, and postoperative pain, and for chronic diseases including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. Clinical practice guidelines from organizations like the World Health Organization, National Institute for Health and Care Excellence, and specialty societies such as the American College of Rheumatology and the European League Against Rheumatism outline indications, dosing, and risk mitigation strategies. In primary care and emergency medicine settings at institutions like Mayo Clinic and Cleveland Clinic, NSAIDs are compared with opioids and acetaminophen for analgesia protocols. In sports medicine and orthopedics, groups including the International Olympic Committee and the American Academy of Orthopaedic Surgeons discuss NSAID use for acute injuries and postoperative pain. Public health agencies such as the Centers for Disease Control and Prevention and Food and Drug Administration provide safety communications on their use in vulnerable populations including older adults, pregnant patients, and those with cardiovascular disease.
NSAIDs primarily inhibit cyclooxygenase enzymes, a discovery explored by researchers associated with institutions like University of Dublin Trinity College, University of Oxford, and Johns Hopkins University School of Medicine. Cyclooxygenase isoforms convert arachidonic acid to prostaglandins and thromboxanes; inhibition reduces prostaglandin-mediated inflammation and pain, and alters platelet function. Studies from laboratories at Harvard Medical School, Stanford University School of Medicine, and the Karolinska Institutet clarified the roles of COX-1 and COX-2 isoenzymes, leading to the development of selective COX-2 inhibitors by companies such as Pfizer and Merck & Co.. Research published through journals affiliated with Cold Spring Harbor Laboratory and the Royal Society expanded understanding of prostanoid signaling pathways. Nobel recognition for work on prostaglandins and related mediators highlights contributions from scientists linked to institutions like the Rockefeller University.
NSAIDs are classified by chemical structure and COX selectivity. Common traditional NSAIDs include salicylates such as aspirin (widely used historically and studied at places like Bayer), propionic acid derivatives like ibuprofen (developed by Boots UK), and naproxen (marketed by Boehringer Ingelheim and Syntex). Acetic acid derivatives include diclofenac (prescribed globally and produced by manufacturers including Novartis), indomethacin, and sulindac. Oxicam derivatives include piroxicam, while fenamates include mefenamic acid. Selective COX-2 inhibitors (coxibs) such as celecoxib and rofecoxib were developed with involvement from pharmaceutical firms like Pfizer and Merck & Co. and evaluated in large randomized trials coordinated at centers like Duke University and Vanderbilt University Medical Center. Topical NSAIDs and combination formulations have been studied in clinical trials sponsored by academic consortia and industry partners, including research networks affiliated with National Institutes of Health and multinational consortia.
NSAIDs are associated with gastrointestinal, renal, cardiovascular, and hematologic adverse effects. Gastrointestinal risks such as peptic ulcer disease, bleeding, and perforation have been characterized in meta-analyses from groups including Cochrane, and management strategies reference guidelines from the American Gastroenterological Association and the European Society of Gastroenterology. Renal effects including acute kidney injury and tubular dysfunction are discussed in nephrology literature from institutions like Mount Sinai Health System and UCLA Health. Cardiovascular risks—myocardial infarction, stroke, heart failure exacerbation—were highlighted in safety communications by the Food and Drug Administration and regulatory actions in the European Union coordinated through the European Medicines Agency. Hypersensitivity reactions, including asthma exacerbation and anaphylaxis, are reported in allergology studies associated with centers such as Mayo Clinic and Imperial College London. Drug-specific adverse-event profiles have influenced prescribing patterns in hospitals such as Massachusetts General Hospital and policy statements from professional societies like the American Heart Association.
Pharmacokinetic properties—absorption, distribution, metabolism, and elimination—vary among NSAIDs and have been delineated in pharmacology texts from universities including Yale School of Medicine and University of California, San Francisco. Many NSAIDs undergo hepatic metabolism via cytochrome P450 isoenzymes with involvement of enzymes characterized in research from University of Cambridge and ETH Zurich, leading to interactions with drugs metabolized by the same pathways, as described in formularies maintained by institutions like British National Formulary and Micromedex. NSAID interactions with anticoagulants such as warfarin (used in clinical practice at centers like The Johns Hopkins Hospital), antiplatelet agents like clopidogrel, and disease-modifying agents used in rheumatology are clinically significant. Considerations for pregnancy, lactation, and pediatric dosing are covered in guidelines from American College of Obstetricians and Gynecologists and American Academy of Pediatrics.
The therapeutic use of salicylate-containing extracts traces to traditional preparations and early modern chemistry involving figures connected to institutions like University of Heidelberg and companies such as Bayer, which commercialized aspirin in the late 19th century. Key 20th-century advances in understanding prostaglandins, with contributors affiliated with Imperial College London and University of Edinburgh, paved the way for synthetic NSAIDs developed by pharmaceutical firms including Roche and Boots UK. The delineation of COX isoforms in the late 20th century, with major research contributions from Washington University in St. Louis and University of California, San Diego, led to the emergence of COX-2 selective inhibitors; regulatory controversies surrounding drugs such as rofecoxib involved agencies including the Food and Drug Administration and legal actions reaching courts like the United States District Court for the Southern District of New York. Ongoing translational research is conducted at institutions such as Massachusetts Institute of Technology and The Scripps Research Institute.
NSAID approval, labeling, and market withdrawal decisions involve regulatory bodies including the Food and Drug Administration, the European Medicines Agency, and national agencies such as Health Canada and the Therapeutic Goods Administration of Australia. Patent litigation and market exclusivity disputes have engaged corporations like Pfizer, Merck & Co., Bayer, and Novartis, and intellectual property cases have proceeded through courts including the Supreme Court of the United States and the European Court of Justice. Over-the-counter availability varies by jurisdiction with guidance from public health agencies such as the Centers for Disease Control and Prevention and reimbursement policies set by insurers like Centers for Medicare & Medicaid Services and national health services including the National Health Service (England). International procurement and essential medicines lists maintained by the World Health Organization influence availability in low- and middle-income countries.
Category:Drugs